Santen Pharmaceutical has logged a strong run in recent years, and the question now is whether that climb is fully explained by what the business earns. With the stock price moving ahead, the key issue is how closely that market enthusiasm lines up with Santen Pharmaceutical’s earnings power.
Over the past 3 years the share price has returned 56.1%, which puts real weight on the question of whether current earnings can carry that kind of gain.
The newly approved share buyback program, which includes cancelling repurchased shares, may support earnings per share if profits hold steady because the same earnings are spread over fewer shares.
Your read on Santen Pharmaceutical is one view; the desks covering it have another. See what analysts think Santen Pharmaceutical’s shares could be worth.
The issue now is whether Santen Pharmaceutical’s current share price is justified by its earnings when set against the Fair Ratio benchmark.
If you are weighing Santen Pharmaceutical’s 56.1% three year return against its earnings story, it can help to compare it with a wider set of stocks filtered by 21 high quality undervalued stocks.
Is Santen Pharmaceutical a Bargain on Earnings?
The P/E ratio is a good fit for Santen Pharmaceutical because earnings remain the main anchor for how this kind of healthcare group is priced. On this measure, the stock trades on about 16.7x earnings, which is mildly above the Pharmaceuticals industry average of roughly 15.4x but below the broader peer group on around 20.7x. That places Santen Pharmaceutical in a middle ground where investors are paying some premium to the sector, yet not as much as for many comparable companies.
The Fair Ratio, which reflects what a tailored P/E might look like after factoring in growth prospects, profitability, scale and risk, comes out higher than where the shares currently trade. Because the board has approved a sizeable buyback that aims to retire almost 5% of outstanding stock, the market is still valuing Santen Pharmaceutical on a lower earnings multiple than this framework would suggest despite that capital return plan. For anyone weighing the recent 3 year share price gain against current earnings power, the gap to this Fair Ratio indicates a P/E that may still be on the undervalued side relative to the company’s fundamentals. Explore the numbers behind Santen Pharmaceutical’s P/E valuation.
TSE:4536 P/E Ratio as at Nov 2026 The Santen Pharmaceutical Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives expand on the P/E and Fair Ratio analysis for Santen Pharmaceutical by explaining which combinations of future growth, margins and earnings would need to occur for the share price to appear meaningfully higher or lower than it does today. Each scenario links Santen Pharmaceutical’s potential catalysts and key risks to a specific estimate of fair value, allowing you to track over time which version of events is actually unfolding on the Community page.
A written, number driven view on Santen Pharmaceutical helps set clear expectations around whether the newly approved share repurchase and planned share cancellations align with the current earnings multiple. It also provides a framework you can revisit as the buyback progresses and as new results show how Santen Pharmaceutical’s actual performance compares with those original assumptions.
Share your own Narrative for Santen Pharmaceutical and set out the assumptions behind your valuation.
The share price is only one question for Santen Pharmaceutical investors
Who actually steers Santen Pharmaceutical, how their interests line up with yours and what they are paid for that role can change the whole risk and reward picture. See who runs Santen Pharmaceutical and how they are paid.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4536.T.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com